Argent BioPharma to delist from LSE; hints at future dual US listing

(Alliance News) - Argent BioPharma Ltd shares slumped on Friday as it said it will delist from ...

Alliance News 29 November, 2024 | 11:52AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Argent BioPharma Ltd shares slumped on Friday as it said it will delist from the London Stock Exchange, and hinted at a potential future dual listing on a US-based exchange.

The Australia-based drug discovery company said its last day of trading on the LSE will be December 31, after the required 20 business days' notice.

Shares in Argent BioPharma sank 27% to 11.35 pence in London on Friday morning.

The company noted that it has a "growing investor base" in the US with operations and management in the EU.

It said it "may still look to explore opportunities to expand its accessibility to investors, including the potential for a dual listing on a United States-based exchange".

The company will maintain its shares on the Australian Securities Exchange and the OTCQB venture market in the US.

Argent BioPharma said it had conducted a "detailed review of both the listing requirements and costs associated with the transfer of all its ordinary shares" to come to the decision.

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Argent Biopharma Ltd
Argent Biopharma Ltd 0.04 AUD 10.53 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures